SARS‐CoV‐2 infection correlates with male benign prostatic hyperplasia deterioration

Alex Qinyang Liu,Peter Ka‐Fung Chiu,Samuel Chi‐Hang Yee,Chi‐Fai Ng,Jeremy Yuen‐Chun Teoh
DOI: https://doi.org/10.1111/joim.13719
2023-10-18
Journal of Internal Medicine
Abstract:Introduction Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) affects extra‐respiratory systems, with small‐scale studies showing worsened male lower urinary tract symptoms (LUTS) after coronavirus disease 2019 (COVID‐19). This study explores the correlation between SARS‐CoV‐2 infection and male benign prostatic hyperplasia (BPH) complications using large‐scale real world data. Materials and methods All male patients attending the public healthcare system in Hong Kong receiving alpha‐blocker monotherapy for LUTS from 2021 to 2022 were included in this study. Patients with and without positive polymerase chain reaction (PCR) test for SARS‐CoV‐2 are selected as the exposure group and control group, respectively. Baseline characteristics are retrieved, with propensity score matching performed to ensure balance of covariates between the two groups. BPH complications were then compared and subgroup analyses were performed. Results After propensity score matching, 17,986 patients were included for analysis, among which half had PCR‐confirmed SARS‐CoV‐2 infection (n = 8993). When compared to controls, the SARS‐CoV‐2 group demonstrated statistically significant higher incidence of retention of urine (4.55% vs. 0.86%, p
medicine, general & internal
What problem does this paper attempt to address?